ABBV vs AMAT Stock Comparison

Scores Breakdown

Metric	ABBV	AMAT
📈 Growth	15/30	28/30
💰 Profitability	16/20	18/20
🏦 Financial Health	12/20	16/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	6/10	6/10
Overall Score	59/100	80/100

Side-by-Side Summaries

ABBV Analysis	AMAT Analysis
📈 Growth & Financial Trajectory 8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1. 💰 Margins & Cash Flow Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings. 🛡️ Balance Sheet & Liquidity Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B. ⚠️ Key Drivers & Risks Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress. Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.	📈 Growth & Financial Trajectory Over the eight quarters, AMAT shows a modest Revenues rise from about $7.05B in Q3 2024 to about $7.91B in Q2 2026, a roughly 12% increase, while Net Income grows from about $1.73B to about $2.81B, up roughly 62%. The trend is broadly positive despite mid-period volatility: Q4 2025 revenue dipped to about $6.8B before rebounding in early 2026. The trajectory suggests improving profitability even as quarterly results oscillate with industry cycles. 💰 Margins & Cash Flow Gross Margin has been resilient, typically in the mid-40s to low-50s, peaking around 51% in Q4 2025 and remaining near 50% in Q2 2026. Operating Margin runs in the low-to-mid 20s percent, with improvements during stronger quarters (roughly 25-32% range). Cash Flow from operating activities was positive in most quarters, supporting investment activity; however, the latest quarter shows a negative total cash flow (-$928M) driven by investing/financing outflows, highlighting cyclicality in capital allocation. 🛡️ Balance Sheet & Liquidity Assets run in the mid-$30s to low-$40s billions with equity typically in the low-to-mid $20s billions; current assets exceed current liabilities by a comfortable margin, yielding a healthy liquidity cushion. Liabilities are manageable, with limited long-term debt in several periods. ⚠️ Key Drivers & Risks Drivers: AI/Data Center demand for semiconductor equipment; ongoing capacity expansion in foundries. Risks: Semiconductor cycle sensitivity and valuation risk; potential margin compression if input costs or pricing pressure rise.

ABBV Analysis

AMAT Analysis

📈 Growth & Financial Trajectory

8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1.

💰 Margins & Cash Flow

Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings.

🛡️ Balance Sheet & Liquidity

Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B.

⚠️ Key Drivers & Risks

Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress.
Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.

📈 Growth & Financial Trajectory

Over the eight quarters, AMAT shows a modest Revenues rise from about $7.05B in Q3 2024 to about $7.91B in Q2 2026, a roughly 12% increase, while Net Income grows from about $1.73B to about $2.81B, up roughly 62%. The trend is broadly positive despite mid-period volatility: Q4 2025 revenue dipped to about $6.8B before rebounding in early 2026. The trajectory suggests improving profitability even as quarterly results oscillate with industry cycles.

💰 Margins & Cash Flow

Gross Margin has been resilient, typically in the mid-40s to low-50s, peaking around 51% in Q4 2025 and remaining near 50% in Q2 2026.
Operating Margin runs in the low-to-mid 20s percent, with improvements during stronger quarters (roughly 25-32% range).
Cash Flow from operating activities was positive in most quarters, supporting investment activity; however, the latest quarter shows a negative total cash flow (-$928M) driven by investing/financing outflows, highlighting cyclicality in capital allocation.

🛡️ Balance Sheet & Liquidity

Assets run in the mid-$30s to low-$40s billions with equity typically in the low-to-mid $20s billions; current assets exceed current liabilities by a comfortable margin, yielding a healthy liquidity cushion. Liabilities are manageable, with limited long-term debt in several periods.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center demand for semiconductor equipment; ongoing capacity expansion in foundries.
Risks: Semiconductor cycle sensitivity and valuation risk; potential margin compression if input costs or pricing pressure rise.

Similar Companies

ABT Score: 72 AMGN Score: 76 BMY Score: 76 GILD Score: 65 JNJ Score: 79 LLY Score: 75 MRK Score: 64 PFE Score: 79

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"